


WHAT IS CLAIMED IS:

1. A compound of Formula (I):



or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, wherein:

ring A is independently phenyl or a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e, O and S; wherein said phenyl and heteroaryl are substituted with 0-1 R⁶ and 0-2 R⁷;

R¹ is independently selected from: -(CH₂)_m-(C₃₋₆ carbocycle substituted with 0-2 R^b and 0-2 R^g), -(CH₂)_m-(5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e, O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g), and (a C₁₋₁₂ hydrocarbon chain substituted with 0-3 R^a; wherein said hydrocarbon chain may be straight or branched, saturated or unsaturated);

R² is independently selected from: C₁₋₄ alkyl, C₃₋₄ cycloalkyl, and C₁₋₄ haloalkyl;

R³ is independently selected from: H, F, C₁₋₄ alkyl and CN;

R⁴ is independently selected from: H, F, and C₁₋₄ alkyl;

R³ and R⁴ may be combined with the carbon atom to which they are attached to form a 3- to 6-membered carbocycle;

R⁶ is independently selected from: halogen, C₁₋₆ alkyl substituted with 0-2 R^h, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, CO(C₁₋₄ alkyl), -(CH₂)_m-C₃₋₆ carbocycle, -(CH₂)_m-NR^fRⁱ, CN, ORⁱ, SRⁱ, and (a 4- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S);

R⁷ is independently selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

alternatively, R⁶ and R⁷, together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic ring or a 5- to 6-membered heterocyclic ring comprising carbon atoms and 1-3 heteroatoms selected from N, NR^e, O, and S; wherein said heterocycle is substituted with 0-2 R^g;

R^a is, at each occurrence, independently selected from: halogen, OH, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, N(C₁₋₄ alkyl)₂, COOH, and -(CH₂)_n-R^c;

R^b is, at each occurrence, independently selected from: halogen, OH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₁₋₁₀ haloalkyl, C₁₋₁₀ haloalkoxy, C₁₋₁₀ alkylthio, C₁₋₁₀ haloalkylthio, N(C₁₋₄ alkyl)₂, -CONH(C₄₋₂₀ alkyl), -CONH(C₄₋₂₀ haloalkyl), -O(CH₂)_sO(C₁₋₆ alkyl), -O(CH₂)_sO(C₁₋₆ haloalkyl), R^c, and -(CH₂)_n-(O)_t-(CH₂)_m-R^c;

R^c is, at each occurrence, independently selected from: C₃₋₆ cycloalkyl substituted with 0-2 R^d, C₃₋₆ cycloalkenyl substituted with 0-2 R^d, -(CH₂)_m-(phenyl substituted with 0-3 R^d), and (a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e, O, and S; wherein said heterocycle is substituted with 0-2 R^d);

R^d is, at each occurrence, independently selected from: halogen, OH, CN, NO₂, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, tetrazolyl, OBn and phenyl;

R^e is, at each occurrence, independently selected from: H, C₁₋₈ alkyl, C₁₋₈ haloalkyl, -(CH₂)_n-C₃₋₆ carbocycle, CO(C₁₋₄ alkyl) and COBn;

R^f is, at each occurrence, independently selected from: H and C₁₋₄ alkyl;

R^g is, at each occurrence, independently selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

R^h is, at each occurrence, independently selected from: OH, halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, and C₁₋₄ haloalkoxy;

Rⁱ is, at each occurrence, independently selected from the group consisting of C₁₋₄ alkyl, C₃₋₄ cycloalkyl and phenyl;

n, at each occurrence, is independently 0 or 1;

m, at each occurrence, is independently 0, 1, 2, 3, or 4;

s, at each occurrence, is independently 1, 2, or 3; and

t, at each occurrence, is independently 0 or 1.

2. A compound according to claim 1, wherein:

R^1 is independently selected from: (C_{3-6} carbocycle substituted with 0-2 R^b and 0-2 R^g), and (a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e , O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g);

R^3 is independently selected from: H, F, C_{1-4} alkyl and CN;

R^4 is independently selected from: H, F, and C_{1-4} alkyl;


R^b is, at each occurrence, independently selected from: halogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{1-10} haloalkyl, C_{1-10} haloalkoxy, C_{1-10} alkylthio, C_{1-10} haloalkylthio, $N(C_{1-4} \text{ alkyl})_2$, $-CONH(C_{4-20} \text{ alkyl})$, $-CONH(C_{4-20} \text{ haloalkyl})$, $-O(CH_2)_sO(C_{1-6} \text{ alkyl})$, $-O(CH_2)_sO(C_{1-6} \text{ haloalkyl})$, R^c , and $-(CH_2)_n-(O)_t-(CH_2)_mR^c$; and

R^d is, at each occurrence, independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkoxy, tetrazolyl, OBn and phenyl.

3. A compound according to claim 1, wherein:

ring A is independently selected from phenyl, pyrrolyl, thienyl, thiazolyl, pyrazolyl, pyridyl, and pyrimidinyl; wherein each ring moiety is substituted with 0-1 R^6 and 0-2 R^7 ; and alternatively, R^6 and R^7 , together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring.

4. A compound according to claim 1, wherein:



R^1 is independently selected from: (phenyl substituted with 1 R^b and 0-2 R^g), and (a 5-membered heteroaryl comprising carbon atoms and 1-2 heteroatoms selected from N, NR^e , O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g);

R^2 is independently selected from: C_{1-4} alkyl and C_{1-4} haloalkyl;

R^6 is independently selected from: halogen, C_{1-6} alkyl with 0-1 OH, C_{1-4} alkoxy, C_{1-4} haloalkoxy, $CO(C_{1-4}$ alkyl), $N(C_{1-4}$ alkyl)₂, and $-(CH_2)_{0-1}-C_{3-6}$ cycloalkyl;

R^7 is independently selected from: halogen, C_{1-4} alkyl and C_{1-4} alkoxy;





alternatively, R^6 and R^7 , together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring;


R^b is, at each occurrence, independently selected from: halogen, C_{1-8} alkyl, C_{1-8} alkoxy, C_{1-8} haloalkyl, C_{1-10} haloalkoxy, and phenoxy;

R^e is, at each occurrence, independently selected from: C_{1-6} alkyl, C_{1-8} haloalkyl, and $-(CH_2)_n-C_{3-6}$ carbocycle; and


R^g is, at each occurrence, independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy.

5. A compound of Formula (IIa), (IIb), (IIc), (IIId), or (IIe):





or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof, within the scope of any of the above aspects, wherein:



R^1 is independently selected from:

R^2 is independently selected from: CF_3 and CH_3 ;


R^6 is independently selected from: halogen, C_{1-4} alkyl substituted with 0-1 OH, C_{1-4} alkoxy, C_{1-4} haloalkoxy, $CO(C_{1-4}$ alkyl), and $-(CH_2)_{0-1}-C_{3-4}$ cycloalkyl;

R^b is independently selected from: $-(CH_2)_{1-6}CF_3$, $-(CH_2)_{1-4}CF_2CF_3$, $-O(CH_2)_{1-6}CF_3$, and $-O(CH_2)_{1-4}CF_2CF_3$;


R^e is, at each occurrence, independently selected from: C_{1-4} alkyl, $-(CH_2)_{1-6}CF_3$, and $-(CH_2)_{0-1}-C_{3-4}$ cycloalkyl; and

R^g is independently halogen.

6. A compound according to claim 5, wherein:



7. A compound according to claim 1, wherein the compound is selected from:




an enantiomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.


8. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1.

9. A pharmaceutical composition comprising a compound according to claim 1 and further comprising a dipeptidyl peptidase-IV (DPP4) inhibitor.

10. A compound according to claim 1 for use in the treatment of diabetes, hyperglycemia, gestational diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hypertension, obesity, dyslipidemia, wherein a therapeutically effective amount of the compound is to be administered to a patient in need of such treatment.


11. A compound selected from:






stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.


12. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




13. A compound according to claim 11, wherein the compound has the following formula:



14. A compound according to claim 11, wherein the compound has the following formula:




15. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

16. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

17. A compound according to claim 11, wherein the compound has the following formula:




18. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

19. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

20. A compound according to claim 11, wherein the compound has the following formula:




21. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

22. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

23. A compound according to claim 11, wherein the compound has the following formula:




24. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

25. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

26. A compound according to claim 11, wherein the compound has the following formula:




27. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

28. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

29. A compound according to claim 11, wherein the compound has the following formula:




30. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

31. A compound according to claim 11, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

32. A compound according to claim 11, wherein the compound has the following formula:




33. A compound according to claim 11, wherein the compound is a racemic mixture of a compound having the following formula:




and its enantiomer, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

34. A compound according to claim 11, wherein the compound has the following formula:



, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

35. A compound according to claim 11, wherein the compound has the following formula:



36. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound according to any one of claims 7, 11 to 35.
37. A pharmaceutical composition comprising a compound according to any one of claims 7, 11 to 35 and further comprising a dipeptidyl peptidase-IV(DPP4) inhibitor.
38. A compound according to any one of claims 7, 11 to 35 for use in the treatment of diabetes, hyperglycemia, gestational diabetes, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, hypertension, obesity, dyslipidemia, wherein a therapeutically effective amount of the compound is to be administered to a patient in need of such treatment.
39. A compound according to claim 1 for use in the treatment of impaired glucose tolerance, insulin resistance, hyperinsulinemia, Metabolic Syndrome, and/or glaucoma, wherein a therapeutically effective amount of the compound is to be administered to a patient in need of such treatment.
40. The compound for use according to claim 39, wherein:

R^1 is independently selected from: (C_{3-6} carbocycle substituted with 0-2 R^b and 0-2 R^g), and (a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NR^e , O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g);

R^3 is independently selected from: H, F, C_{1-4} alkyl and CN;

R^4 is independently selected from: H, F, and C_{1-4} alkyl;

R^b is, at each occurrence, independently selected from: halogen, C_{1-10} alkyl, C_{1-10} alkoxy, C_{1-10} haloalkyl, C_{1-10} haloalkoxy, C_{1-10} alkylthio, C_{1-10} haloalkylthio, $N(C_{1-4} \text{ alkyl})_2$, $-CONH(C_{4-20}$


alkyl), -CONH(C₄₋₂₀ haloalkyl), -O(CH₂)_sO(C₁₋₆ alkyl), -O(CH₂)_sO(C₁₋₆ haloalkyl), R^c, and -(CH₂)_n-(O)_t-(CH₂)_mR^c; and

R^d is, at each occurrence, independently selected from: halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ haloalkyl, C₁₋₄ haloalkoxy, tetrazolyl, OBn and phenyl.

41. The compound for use according to claim 39, wherein:

ring A is independently selected from phenyl, pyrrolyl, thienyl, thiazolyl, pyrazolyl, pyridyl, and pyrimidinyl; wherein each ring moiety is substituted with 0-1 R⁶ and 0-2 R⁷; and alternatively, R⁶ and R⁷, together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring.

42. The compound for use according to claim 39, wherein:



R¹ is independently selected from: (phenyl substituted with 1 R^b and 0-2 R^g), and (a 5-membered heteroaryl comprising carbon atoms and 1-2 heteroatoms selected from N, NR^e, O and S; wherein said heteroaryl is substituted with 0-1 R^b and 0-2 R^g);

R² is independently selected from: C₁₋₄ alkyl and C₁₋₄ haloalkyl;

R⁶ is independently selected from: halogen, C₁₋₆ alkyl with 0-1 OH, C₁₋₄ alkoxy, C₁₋₄ haloalkoxy, CO(C₁₋₄ alkyl), N(C₁₋₄ alkyl)₂, and -(CH₂)₀₋₁-C₃₋₆ cycloalkyl;

R⁷ is independently selected from: halogen, C₁₋₄ alkyl and C₁₋₄ alkoxy;

alternatively, R⁶ and R⁷, together with the carbon atoms to which they are attached, combine to form a 6-membered carbocyclic ring;


R^b is, at each occurrence, independently selected from: halogen, C₁₋₈ alkyl, C₁₋₈ alkoxy, C₁₋₈ haloalkyl, C₁₋₁₀ haloalkoxy, and phenoxy;

R^e is, at each occurrence, independently selected from: C_{1-6} alkyl, C_{1-8} haloalkyl, and $-(CH_2)_n-C_{3-6}$ carbocycle; and


R^g is, at each occurrence, independently selected from: halogen, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} haloalkyl, and C_{1-4} haloalkoxy.


43. A compound according to claim 5 for use in the treatment of impaired glucose tolerance, insulin resistance, hyperinsulinemia, Metabolic Syndrome, and/or glaucoma, wherein a therapeutically effective amount of the compound is to be administered to a patient in need of such treatment.

44. The compound for use according to claim 43, wherein:




45. The compound for use according to claim 39, wherein the compound is selected from:








, and , or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

46. The compound for use according to claim 39, wherein the compound is selected from:











or an enantiomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.


47. The compound for use according to claim 46, wherein the compound has the following formula:



48. The compound for use according to claim 46, wherein the compound has the following formula:




49. The compound for use according to claim 46, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

50. The compound for use according to claim 46, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

51. The compound for use according to claim 46, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

52. The compound for use according to claim 46, wherein the compound has the following formula:




, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

53. The compound for use according to claim 46, wherein the compound has the following formula:



, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.

54. The compound for use according to claim 46, wherein the compound has the following formula:



, or a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof.